Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Biotechnology

Healthcare
$31.49 -0.03%

-$0.01 today

Market cap
$3.85B
Beta
0.74
P/E (TTM)
17.3
EPS (TTM)
$1.81
52W Low $19.05High $32.56

Volume 0.00M

Average 2.17M

CPRX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) dips below year-ago levels

Q1 FY2026 weighted avg shares (diluted) of 126.9M shares fell 0.0% year over year, behind the +1.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.0% toward the trailing-twelve-month pace of +1.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
126.9M-0.3% QoQ
Last fiscal yearDec 2025
127.26M+1.9% YoY
LTMMar 2026
127.2M+1.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.0%——
1 year+1.9%——
3-year CAGR+4.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
127.26M USD
Year-over-year change
+1.9%
4-year CAGR
+4.2%

Weighted Avg Shares (Diluted) vs competitors

How CPRX compares with its peers on the latest reported figures

  • CPRX's LTM Mar 2026 weighted avg shares (diluted) of 127.2M shares is the 3rd highest of the 9 companies compared; the peer median is 96.32M shares.
  • Its year-over-year change of +1.1% is the lowest of 9, against a peer median of +11.8%.
  • Over three fiscal years its annual growth of +4.5% compares with a peer median of +18.3%.
CPRX Competitors Peer median
Weighted Avg Shares (Diluted) for CPRX and competitors
Company Period LTM YoY 3-year CAGR
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026508.87M +41.5%+36.6%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026157.38M +5.6%+2.1%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026127.2M +1.1%+4.5%
SRRKScholar Rock Holding CorporationLTM Sep 2026126.24M +15.3%+24.4%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.77M +17.0%+12.2%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.86M +4.6%+28.8%
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 202680.7M +8.3%+3.9%
MLYSMineralys Therapeutics, Inc.LTM Jun 202679.68M +45.9%+135.7%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 202658.3M +1.5%+1.9%
Peer median (excluding CPRX) 96.32M+11.8%+18.3%

Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.83M214.2M398.2M491.73M588.99M
Cost of Revenue21.88M34.39M51.97M68.85M87.25M
Gross Profit118.95M179.81M346.24M422.89M501.74M
Gross Margin84.5%83.9%86.9%86.0%85.2%
Research & Development16.94M19.79M93.15M12.65M12.71M
Selling, General & Admin49.63M57.09M133.71M177.74M193.75M
Operating Expenses66.56M77.97M259.43M227.77M243.96M
Depreciation & Amortization192K1.24M32.88M37.77M37.87M
EBITDA52.86M105.96M127.39M254.04M321.39M
EBITDA Margin37.5%49.5%32.0%51.7%54.6%
Operating Income52.39M101.84M86.81M195.12M257.78M
Operating Margin37.2%47.5%21.8%39.7%43.8%
Interest Income00016.06M0
Interest Expense00000
Other Income / Expenses282K2.88M7.7M21.14M25.74M
Income Before Tax52.67M104.72M94.51M216.26M283.52M
Pre-Tax Margin37.4%48.9%23.7%44.0%48.1%
Income Tax Expense13.19M21.64M23.1M52.37M69.19M
Net Income39.48M83.08M71.41M163.89M214.33M
Net Margin28.0%38.8%17.9%33.3%36.4%
EPS (Basic)0.380.800.671.381.75
EPS (Diluted)0.370.750.631.311.68
Weighted Avg Shares103.38M103.37M106.28M118.46M122.29M
Weighted Avg Shares (Diluted)107.8M111.38M113.75M124.94M127.26M

Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Intrinsic Alpha fair value

Locked

Current Price

$31.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.